Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt

AstraZeneca1 site in 1 country3,170 target enrollmentJuly 2012

ConditionsPatients With Upper Gastro-intestinal Symptoms

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Patients With Upper Gastro-intestinal Symptoms
Sponsor: AstraZeneca
Enrollment: 3170
Locations: 1
Primary Endpoint: Percentage of patients scoring ≥ 8 in GERD-Q
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.

Detailed Description

Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt

Registry

clinicaltrials.gov

Start Date

July 2012

End Date

July 2014

Last Updated

11 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•18 years and above
•Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting.

Exclusion Criteria

•Participating on a clinical trial during the last 3 months.
•Patients not able to read and/or understand the GERD-Q questionnaire.
•Patients already included in the study in other participating site.
•Patients taking PPIs or H2blockers in the l

Outcomes

Primary Outcomes

Percentage of patients scoring ≥ 8 in GERD-Q

Time Frame: baseline

Percentage of patients scoring ≥ 8 in GERD-Q will be considered as suffering from GERD. The GERD-Q is a potentially useful tool for family practitioners and other health care professionals in diagnosing and managing GERD without initial specialist referral or endoscopy. The Egyptian-validated version of the GERD-Q will be used for the study purposes.

Secondary Outcomes

Treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD)(baseline)
Socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD)(baseline)